Gene · 7329
Papers3,237
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,237
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Accessory ESCRT-III proteins are conserved and selective regulators of Rab11a-exosome formation. | J Extracell Vesicles | 2023 | 36872252 | PubTator, text mining | PubMed |
| Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. | Cancer Commun (Lond) | 2023 | 36855844 | PubTator, text mining | PubMed |
| Emerging Role of Plant-Based Dietary Components in Post-Translational Modifications Associated with Colorectal Cancer. | Life (Basel) | 2023 | 36836621 | PubTator, text mining | PubMed |
| Emerging Mechanisms of Skeletal Muscle Homeostasis and Cachexia: The SUMO Perspective. | Cells | 2023 | 36831310 | PubTator, text mining | PubMed |
| Post-ovulatory aging is associated with altered patterns for small ubiquitin-like modifier (SUMO) proteins and SUMO-specific proteases. | FASEB J | 2023 | 36826436 | PubTator, text mining | PubMed |
| Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export. | Mol Carcinog | 2023 | 36825757 | PubTator, text mining | PubMed |
| Glioblastoma upregulates SUMOylation of hnRNP A2/B1 to eliminate the tumor suppressor miR-204-3p, accelerating angiogenesis under hypoxia. | Cell Death Dis | 2023 | 36810326 | PubTator, text mining | PubMed |
| TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. | Blood Adv | 2023 | 36809797 | PubTator, text mining | PubMed |
| Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review). | Oncol Rep | 2023 | 36799184 | PubTator, text mining | PubMed |
| Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. | Theranostics | 2023 | 36793866 | PubTator, text mining | PubMed |
| Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. | Leukemia | 2023 | 36792656 | PubTator, text mining | PubMed |
| Crosstalk between PML and p53 in response to TGF-β1: A new mechanism of cardiac fibroblast activation. | Int J Biol Sci | 2023 | 36778116 | PubTator, text mining | PubMed |
| CHD1, a multifaceted epigenetic remodeler in prostate cancer. | Front Oncol | 2023 | 36776288 | PubTator, text mining | PubMed |
| The Functional Roles of ISG15/ISGylation in Cancer. | Molecules | 2023 | 36771004 | PubTator, text mining | PubMed |
| Aurora B SUMOylation Is Restricted to Centromeres in Early Mitosis and Requires RANBP2. | Cells | 2023 | 36766713 | PubTator, text mining | PubMed |
| The Rosetta Stone Hypothesis-Based Interaction of the Tumor Suppressor Proteins Nit1 and Fhit. | Cells | 2023 | 36766695 | PubTator, text mining | PubMed |
| Reduced SUMOylation of Nrf2 signaling contributes to its inhibition induced by amyloid-β. | Neurosci Lett | 2023 | 36764479 | PubTator, text mining | PubMed |
| HDAC4 in cancer: A multitasking platform to drive not only epigenetic modifications. | Front Mol Biosci | 2023 | 36762207 | PubTator, text mining | PubMed |
| Alternative splicing of the SUMO1/2/3 transcripts affects cellular SUMOylation and produces functionally distinct SUMO protein isoforms. | Sci Rep | 2023 | 36759644 | PubTator, text mining | PubMed |
| Mitotic DNA synthesis in response to replication stress requires the sequential action of DNA polymerases zeta and delta in human cells. | Nat Commun | 2023 | 36759509 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7329/papers?page=16